Online inquiry

IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ424MR)

This product GTTS-WQ424MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets AMHR2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001164690.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 269
UniProt ID Q16671
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ424MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2951MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ6512MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ13881MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ474MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ4814MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ11754MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ6076MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ12336MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW